ZZZhizhuang Joe Zhao

Zhizhuang Joe Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhizhuang Joe Zhao has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Sanford B. Krantz

    Division of Hematology/Oncology, Department of Medicine, Department of Veterans Affairs Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee 37232

    4 shared publications
  • Brett P. Monia

    From the Division of Hematology/Oncology, Department of Medicine, Department of Pathology, Department of Veterans Affairs Medical Service, and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN; and the Department of Molecular Pharmacology, Isis Pharmaceuticals, Carlsbad, CA

    2 shared publications
  • James O. Price

    From the Division of Hematology/Oncology, Department of Medicine, Department of Pathology, Department of Veterans Affairs Medical Service, and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN; and the Department of Molecular Pharmacology, Isis Pharmaceuticals, Carlsbad, CA

    2 shared publications
  • Rujiao Shan

    From the Division of Hematology/Oncology, Department of Medicine, Department of Pathology, Department of Veterans Affairs Medical Service, and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN; and the Department of Molecular Pharmacology, Isis Pharmaceuticals, Carlsbad, CA

    2 shared publications
  • Runxiang Zhao

    Division of Hematology/Oncology, Department of Medicine, Department of Veterans Affairs Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee 37232

    2 shared publications
  • William A. Gaarde

    From the Division of Hematology/Oncology, Department of Medicine, Department of Pathology, Department of Veterans Affairs Medical Service, and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN; and the Department of Molecular Pharmacology, Isis Pharmaceuticals, Carlsbad, CA

    2 shared publications

Latest Publications

  • Purification and characterization of protein tyrosine phosphatase PTP‐MEG2

    by Ying Qi, Runxiang Zhao, Hongxi Cao, Xingwei Sui, Sanford B. Krantz, Z. Joe Zhao

    PTP‐MEG2 is an intracellular protein tyrosine phosphatase with a putative lipid‐binding domain at the N‐terminus. The present study reports expression, purification, and characterization of the full‐length form of the enzyme plus a truncated form containing the catalytic domain alone. Full‐length PTP‐MEG2 was expressed with an adenovirus system and purified from cytosolic extracts of human 293 cells infected with the recombinant adenovirus. The purification scheme included chromatographic separation of cytosolic extracts on fast flow Q‐Sepharose, heparin‐agarose, l‐histidyldiazobenzylphosphonic acid agarose, and hydroxylapatite. The enrichment of PTP‐MEG2 from the cytosol was about 120‐fold. The truncated form of PTP‐MEG2 was expressed in E. coli cells as a non‐fusion protein and purified by using a chromatographic procedure similar to that used for the full‐length enzyme. The purified full‐length and truncated enzymes showed single polypeptide bands on SDS–polyacrylamide gel electrophoresis under reducing conditions and behaved as monomers on gel exclusion chromatography. With para‐nitrophenylphosphate and phosphotyrosine as substrates, both forms of the enzyme exhibited classical Michaelis‐Menten kinetics. Their responses to pH, ionic strength, metal ions, and protein phosphatase inhibitors are similar to those observed with other characterized tyrosine phosphatases. Compared with full‐length PTP‐MEG2, the truncated ΔPTP‐MEG2 displayed significantly higher Vmax and lower Km values, suggesting that the N‐terminal putative lipid‐binding domain may have an inhibitory role. The full‐length and truncated forms of PTP‐MEG2 were also expressed as GST fusion proteins in E. coli cells and purified to near homogeneity through affinity columns. However, the specific phosphatase activities of the GST fusion proteins were 10–25‐fold below those obtained with the correspondent non‐fusion proteins. J. Cell. Biochem. 86: 79–89, 2002.


  • Open Access

    Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways

    by Xingwei Sui, Sanford B. Krantz, Zhizhuang Joe Zhao

    Erythropoietin (EPO) and stem cell factor (SCF) are two important factors in human erythropoiesis. We have recently demonstrated that SCF and EPO synergistically activate mitogen‐activated protein (MAP) kinase, thereby promoting growth of human erythroid colony‐forming cells (ECFCs). In the present study, we have examined the intracellular mechanisms by which SCF and EPO maintain survival of these cells. In the absence of SCF and EPO, human ECFCs underwent rapid apoptosis. The process was significantly inhibited by addition of a single factor and was totally prevented in the presence of both factors. Treatment of ECFCs with wortmannin, a specific inhibitor of phosphoinositide 3‐kinase (PI3K), inhibited the antiapoptotic effect of SCF but had no effect on that of EPO, indicating that SCF but not EPO inhibits apoptosis through the PI3K pathway. In contrast, treatment of ECFCs with PD98059, a specific inhibitor of MAP kinase/ERK kinase (MEK), inhibited cell growth but had no effect on the antiapoptotic activity of either SCF or EPO, suggesting that SCF and EPO prevent apoptosis of human ECFCs independent of the extracellular signal‐regulated kinase (ERK) pathway. Interestingly, both EPO and SCF induced activation of PI3K. However, through PI3K, SCF caused activation of protein kinase B (PKB), an anti‐apoptosis signal, whereas EPO led to activation of ERKs. Furthermore, the SCF‐ and EPO‐maintained expression of antiapoptotic protein Bcl‐XL was correlated with the activation of ERKs and was inhibited by PD98059, suggesting that Bcl‐XL may not have a major role in preventing apoptosis of human ECFCs. Phosphorylated BAD was not affected by SCF, EPO or wortmannin. Taken together with our previous results, the present study indicates that SCF and EPO support survival and growth of human ECFCs through different signalling pathways and that they transduce distinctly different signals through activation of PI3K.


  • Open Access

    Distinct Roles of JNKs/p38 MAP Kinase and ERKs in Apoptosis and Survival of HCD-57 Cells Induced by Withdrawal or Addition of Erythropoietin

    by Rujiao Shan, James O. Price, William A. Gaarde, Brett P. Monia, Sanford B. Krantz, Zhizhuang Joe Zhao

    Erythropoietin (EPO), a major regulator of erythroid progenitor cells, is essential for the survival, proliferation, and differentiation of immature erythroid cells. To gain insight into the molecular mechanism by which EPO functions, we analyzed the activation of Jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs) in HCD-57 cells, a murine erythroid progenitor cell line that requires EPO for survival and proliferation. Withdrawal of EPO from the cell culture medium resulted in sustained activation of JNKs plus p38 MAP kinase, and inactivation of ERKs, preceding apoptosis of the cells. Addition of EPO to the EPO-deprived cells caused activation of ERKs accompanied by inactivation of JNKs and p38 MAP kinase and rescued the cells from apoptosis. Phorbol 12-myristate 13-acetate, which activated ERKs by a different mechanism, also suppressed the activation of JNKs and significantly retarded apoptosis of the cells caused by withdrawal of EPO. Furthermore, MEK inhibitor PD98059, which inhibited activation of ERKs, caused activation of JNKs, whereas suppression of JNK expression by antisense oligonucleotides and inhibition of p38 MAP kinase by SB203580 caused attenuation of the apoptosis that occurs upon withdrawal of EPO. Finally, the activation of JNKs and p38 MAP kinase and concurrent inactivation of ERKs upon withdrawal of EPO were also observed in primary human erythroid colony-forming cells. Taken together, the data suggest that activation of ERKs promotes cell survival, whereas activation of JNKs and p38 MAP kinase leads to apoptosis and EPO functions by controlling the dynamic balance between ERKs and JNKs.


  • Retracted
    Open Access

    Distinct Roles of JNKs/p38 MAP Kinase and ERKs in Apoptosis and Survival of HCD-57 Cells Induced by Withdrawal or Addition of Erythropoietin

    by Rujiao Shan, James O. Price, William A. Gaarde, Brett P. Monia, Sanford B. Krantz, Zhizhuang Joe Zhao

    Erythropoietin (EPO), a major regulator of erythroid progenitor cells, is essential for the survival, proliferation, and differentiation of immature erythroid cells. To gain insight into the molecular mechanism by which EPO functions, we analyzed the activation of Jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs) in HCD-57 cells, a murine erythroid progenitor cell line that requires EPO for survival and proliferation. Withdrawal of EPO from the cell culture medium resulted in sustained activation of JNKs plus p38 MAP kinase, and inactivation of ERKs, preceding apoptosis of the cells. Addition of EPO to the EPO-deprived cells caused activation of ERKs accompanied by inactivation of JNKs and p38 MAP kinase and rescued the cells from apoptosis. Phorbol 12-myristate 13-acetate, which activated ERKs by a different mechanism, also suppressed the activation of JNKs and significantly retarded apoptosis of the cells caused by withdrawal of EPO. Furthermore, MEK inhibitor PD98059, which inhibited activation of ERKs, caused activation of JNKs, whereas suppression of JNK expression by antisense oligonucleotides and inhibition of p38 MAP kinase by SB203580 caused attenuation of the apoptosis that occurs upon withdrawal of EPO. Finally, the activation of JNKs and p38 MAP kinase and concurrent inactivation of ERKs upon withdrawal of EPO were also observed in primary human erythroid colony-forming cells. Taken together, the data suggest that activation of ERKs promotes cell survival, whereas activation of JNKs and p38 MAP kinase leads to apoptosis and EPO functions by controlling the dynamic balance between ERKs and JNKs.